Assembly Biosciences ASMB Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Assembly Biosciences in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.
The official record: Assembly Biosciences’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Assembly Biosciences's deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Assembly Biosciences's deferred revenue?
- Assembly Biosciences (ASMB) reported deferred revenue of $29.08M in Q1 2026.
- How has Assembly Biosciences's deferred revenue changed year-over-year?
- Assembly Biosciences's deferred revenue decreased by 28.8% year-over-year, from $40.82M to $29.08M.
- What is the long-term trend for Assembly Biosciences's deferred revenue?
- Over 2 years (2023 to 2025), Assembly Biosciences's deferred revenue has grown at a 9.3% compound annual growth rate (CAGR), from $30.92M to $36.9M.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.